CN110891571A - 吸入性肺炎、肺化脓或肺脓肿的治疗剂 - Google Patents

吸入性肺炎、肺化脓或肺脓肿的治疗剂 Download PDF

Info

Publication number
CN110891571A
CN110891571A CN201880039674.9A CN201880039674A CN110891571A CN 110891571 A CN110891571 A CN 110891571A CN 201880039674 A CN201880039674 A CN 201880039674A CN 110891571 A CN110891571 A CN 110891571A
Authority
CN
China
Prior art keywords
genus
bacteria
belonging
therapeutic agent
fluoro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880039674.9A
Other languages
English (en)
Chinese (zh)
Inventor
小田岛正明
谷冈幸代子
须之内孝明
田渊亚沙子
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Xinglin Pharmaceutical Holdings Co ltd
Original Assignee
Kyorin Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyorin Pharmaceutical Co Ltd filed Critical Kyorin Pharmaceutical Co Ltd
Priority to CN202511420285.9A priority Critical patent/CN121197162A/zh
Priority to CN202310755318.XA priority patent/CN116549446A/zh
Priority claimed from PCT/JP2018/022846 external-priority patent/WO2018230686A1/ja
Publication of CN110891571A publication Critical patent/CN110891571A/zh
Priority to CN202512007503.2A priority patent/CN121466090A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
CN201880039674.9A 2017-06-16 2018-06-15 吸入性肺炎、肺化脓或肺脓肿的治疗剂 Pending CN110891571A (zh)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CN202511420285.9A CN121197162A (zh) 2017-06-16 2018-06-15 吸入性肺炎、肺化脓或肺脓肿的治疗剂
CN202310755318.XA CN116549446A (zh) 2017-06-16 2018-06-15 吸入性肺炎、肺化脓或肺脓肿的治疗剂
CN202512007503.2A CN121466090A (zh) 2017-06-16 2025-06-15 吸入性肺炎、肺化脓或肺脓肿的治疗剂

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762520961P 2017-06-16 2017-06-16
US62/520961 2017-06-16
JP2018068159 2018-03-30
JP2018-068159 2018-03-30
PCT/JP2018/022846 WO2018230686A1 (ja) 2017-06-16 2018-06-15 誤嚥性肺炎、肺化膿症又は肺膿瘍の治療剤

Related Child Applications (3)

Application Number Title Priority Date Filing Date
CN202310755318.XA Division CN116549446A (zh) 2017-06-16 2018-06-15 吸入性肺炎、肺化脓或肺脓肿的治疗剂
CN202511420285.9A Division CN121197162A (zh) 2017-06-16 2018-06-15 吸入性肺炎、肺化脓或肺脓肿的治疗剂
CN202512007503.2A Division CN121466090A (zh) 2017-06-16 2025-06-15 吸入性肺炎、肺化脓或肺脓肿的治疗剂

Publications (1)

Publication Number Publication Date
CN110891571A true CN110891571A (zh) 2020-03-17

Family

ID=66213244

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880039674.9A Pending CN110891571A (zh) 2017-06-16 2018-06-15 吸入性肺炎、肺化脓或肺脓肿的治疗剂

Country Status (14)

Country Link
US (1) US20210137913A1 (https=)
EP (1) EP3639826A4 (https=)
JP (3) JP6618660B2 (https=)
KR (1) KR20200016960A (https=)
CN (1) CN110891571A (https=)
AU (1) AU2018283234A1 (https=)
BR (1) BR112019025960A2 (https=)
CA (1) CA3067188A1 (https=)
CL (1) CL2019003630A1 (https=)
IL (1) IL270831A (https=)
MX (1) MX2019014931A (https=)
PH (1) PH12019502835A1 (https=)
SG (1) SG11201911826VA (https=)
TW (1) TWI818910B (https=)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101513405A (zh) * 1999-12-22 2009-08-26 H-H·舒尔茨 化疗剂的应用
WO2016148066A1 (ja) * 2015-03-13 2016-09-22 杏林製薬株式会社 呼吸器感染症治療剤

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100410249C (zh) 2003-09-10 2008-08-13 杏林制药株式会社 7-(4-取代-3-环丙基氨基甲基-1-吡咯烷基)喹诺酮羧酸衍生物
SA112330992B1 (ar) 2011-11-10 2015-09-13 كيورين فارماسوتيكال كو.، ليمتد صورة متبلرة من 7-{(s4، s3)-3-[(سيكلو بروبيل أمينو) ميثيل]-4-فلورو بيروليدين-1-يل}-6-فلورو-1-(2-فلورو إيثيل)- 8-ميثوكسي-4-أوكسو-1، 4-داي هيدرو كينولين-3- حمض كربوكسيلي
EP3305294A4 (en) * 2015-06-02 2019-02-20 Kyorin Pharmaceutical Co., Ltd. AQUEOUS MEDICINE

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101513405A (zh) * 1999-12-22 2009-08-26 H-H·舒尔茨 化疗剂的应用
WO2016148066A1 (ja) * 2015-03-13 2016-09-22 杏林製薬株式会社 呼吸器感染症治療剤

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
M. ALLEWELT: "Ampicillin + sulbactam vs. clindamycin ± cephalosporin for the treatment of aspiration pneumonia and primary lung abscess", 《CLINICAL MICROBIOLOGY AND INFECTION》 *
Y. YAMAGISHI ETAL: "AM-1977, A New Generation Broad Spectrum Fluoroquinolone:In Vitro Antibacterial Activity Against Anaerobes Isolated in Japan", 《HTTPS://WWW.ABSTRACTSONLINE.COM/PLAN/VIEWABSTRACT.ASPX?SKEY=37B09DCF-F2B5-4E67-AA0D-3F43F3FC4972&CKEY=A363CEE5-EE4A-409F-814B-185B3597B2E5&MKEY=7A574A80-EABL-4B50-B343-4695DF14907E》 *
何礼贤: "《肺部感染性疾病》", 30 November 1996, 上海亦可大学出版社 *
覃燕玲 等: "临床药师参与抗感染治疗的实践和体会", 《实用药物与临床》 *

Also Published As

Publication number Publication date
KR20200016960A (ko) 2020-02-17
TW201906607A (zh) 2019-02-16
IL270831A (en) 2020-01-30
PH12019502835A1 (en) 2020-10-05
JP6671532B2 (ja) 2020-03-25
JP2020079330A (ja) 2020-05-28
AU2018283234A1 (en) 2019-12-12
MX2019014931A (es) 2020-02-13
US20210137913A1 (en) 2021-05-13
CL2019003630A1 (es) 2020-07-10
JP2020015769A (ja) 2020-01-30
EP3639826A4 (en) 2021-03-03
JPWO2018230686A1 (ja) 2019-12-12
JP6618660B2 (ja) 2019-12-11
EP3639826A1 (en) 2020-04-22
TWI818910B (zh) 2023-10-21
JP7098671B2 (ja) 2022-07-11
CA3067188A1 (en) 2018-12-20
SG11201911826VA (en) 2020-01-30
BR112019025960A2 (pt) 2020-11-03

Similar Documents

Publication Publication Date Title
US10231975B2 (en) Use of aerosolized levofloxacin for treating cystic fibrosis
Wise Maximizing efficacy and reducing the emergence of resistance
CN102711760A (zh) 雾化抗生素用于治疗慢性阻塞性肺病的用途
CN110891571A (zh) 吸入性肺炎、肺化脓或肺脓肿的治疗剂
HK40098387A (zh) 吸入性肺炎、肺化脓或肺脓肿的治疗剂
CN116549446A (zh) 吸入性肺炎、肺化脓或肺脓肿的治疗剂
HK40026671A (en) Therapeutic agent for aspiration pneumonia, lung suppuration, or lung abscess
US20030073625A1 (en) Methods of preventing ventilator associated pneumonia by oral administration of antimicrobial IB-367 peptides
AU2015275224C1 (en) Use of aerosolized levofloxacin for treating cystic fibrosis
HK40067557B (zh) 呼吸器官感染治疗剂
US20230310467A1 (en) PHARMACEUTICAL COMBINATION THERAPY AND PREVENTION WITH APROTININ + REMDESIVIR OF SARS-CoV-2 AND/OR DISEASE ASSOCIATED WITH THIS INFECTION, INCLUDI COVID-19
HK1168786B (en) Use of aerosolized levofloxacin for treating cystic fibrosis

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information
CB02 Change of applicant information

Country or region after: Japan

Address after: 3-7 Otemachi 1-chome, Chiyoda ku, Tokyo, Japan

Applicant after: KYORIN PHARMACEUTICAL Co.,Ltd.

Address before: Japan Tokyo Chiyoda Kanda Surugadai four chome 6 GA

Applicant before: Xinglin Pharmaceutical Holdings Co.,Ltd.

Country or region before: Japan

TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20241029

Address after: Japan Tokyo Chiyoda Kanda Surugadai four chome 6 GA

Applicant after: Xinglin Pharmaceutical Holdings Co.,Ltd.

Country or region after: Japan

Address before: Japan Tokyo Chiyoda Kanda Surugadai four chome 6 GA

Applicant before: KYORIN PHARMACEUTICAL Co.,Ltd.

Country or region before: Japan